Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation

J Am Acad Dermatol. 2014 Sep;71(3):e97-9. doi: 10.1016/j.jaad.2014.03.038.

Authors

Julie Charles¹, Jean-Claude Beani², Giacomo Fiandrino³, Benoit Busser⁴

Affiliations

¹ Dermatology Unit, Univ. Grenoble Alpes, IAB, CHU de Grenoble, F-38000 Grenoble, France. Electronic address: [email protected].
² Dermatology Unit, Univ. Grenoble Alpes, IAB, CHU de Grenoble, F-38000 Grenoble, France.
³ Department of Pathology, CHU de Grenoble, F-38000 Grenoble, France.
⁴ Cancer Clinical Laboratory, Univ. Grenoble Alpes, IAB, CHU de Grenoble, F-38000 Grenoble, France.

PMID: 25128147
DOI: 10.1016/j.jaad.2014.03.038

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Female
Histiocytosis, Langerhans-Cell / drug therapy*
Histiocytosis, Langerhans-Cell / genetics*
Histiocytosis, Langerhans-Cell / pathology
Humans
Indoles / administration & dosage
Indoles / therapeutic use*
Mutation
Proto-Oncogene Proteins B-raf / genetics*
Sulfonamides / administration & dosage
Sulfonamides / therapeutic use*
Vemurafenib

Substances

Indoles
Sulfonamides
Vemurafenib
Proto-Oncogene Proteins B-raf